Drug interactions
Ciltacabtagene autoleucel + Ipilimumab
Severity: Moderate
Ciltacabtagene autoleucel and Ipilimumab: moderate interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Ipilimumab is an immune checkpoint inhibitor that stimulates T cells, while ciltacabtagene autoleucel is a CAR-T product with a high risk of cytokine release syndrome and neurotoxicity. Combining them could amplify immune-mediated toxicity, and CAR-T recipients are often already immunocompromised. No formal combination data exist.
What this interaction means in plain words
Ciltacabtagene autoleucel and Ipilimumab can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken.
Ciltacabtagene autoleucel belongs to Miscellaneous; Ipilimumab belongs to Oncology.
Why it happens
Additive immune modulation: checkpoint blockade may enhance CAR-T activation and immune-mediated toxicity; the interaction is largely theoretical.
What to do
Avoid starting ipilimumab around the time of CAR-T infusion unless clearly necessary. If used, monitor closely for cytokine release syndrome, neurotoxicity, immune-related adverse events and infection.
What to ask your pharmacist
- Should I take them at different times of day?
- Does the dose of either medicine need to change?
- Is there anything I should avoid, such as alcohol or certain foods, while on both?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Ciltacabtagene autoleucel and Ipilimumab, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 14 days on the web. No card needed.
Other interactions of Ipilimumab
- Etrasimod + Ipilimumab Major
- Ipilimumab + Vemurafenib Major
- Efgartigimod / hyaluronidase sc + Ipilimumab Moderate
- Efgartigimod alfa + Ipilimumab Moderate
- Idecabtagene vicleucel + Ipilimumab Moderate
- Ipilimumab + Lisocabtagene maraleucel Moderate
Other interactions of Ciltacabtagene autoleucel
Frequently asked questions
Can I take Ciltacabtagene autoleucel with Ipilimumab?
MediHelp rates the interaction as moderate. Ciltacabtagene autoleucel and Ipilimumab can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken. Ipilimumab is an immune checkpoint inhibitor that stimulates T cells, while ciltacabtagene autoleucel is a CAR-T product with a high risk of cytokine release syndrome and neurotoxicity. Combining them could amplify immune-mediated toxicity, and CAR-T recipients are often already immunocompromised. No formal combination data exist.
How serious is the interaction between Ciltacabtagene autoleucel and Ipilimumab?
MediHelp rates it moderate, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Avoid starting ipilimumab around the time of CAR-T infusion unless clearly necessary. If used, monitor closely for cytokine release syndrome, neurotoxicity, immune-related adverse events and infection.
What other medicines interact with Ipilimumab?
MediHelp also lists interactions of Ipilimumab with, for example, Etrasimod, Vemurafenib, Efgartigimod / hyaluronidase sc. The full list is on the Ipilimumab page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
